Compare · CGC vs NAGE
CGC vs NAGE
Side-by-side comparison of Canopy Growth Corporation (CGC) and Niagen Bioscience Inc. (NAGE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGC and NAGE operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- CGC is the larger of the two at $2.86B, about 10.9x NAGE ($262.0M).
- Over the past year, CGC is down 11.7% and NAGE is down 70.3% - CGC leads by 58.6 points.
- NAGE has been more active in the news (17 items in the past 4 weeks vs 11 for CGC).
- CGC has more recent analyst coverage (19 ratings vs 1 for NAGE).
- Company
- Canopy Growth Corporation
- Niagen Bioscience Inc.
- Price
- $0.96-0.79%
- $3.29-5.18%
- Market cap
- $2.86B
- $262.0M
- 1M return
- -5.11%
- -3.94%
- 1Y return
- -11.67%
- -70.29%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 11
- 17
- Recent ratings
- 19
- 1
Canopy Growth Corporation
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flowers, oils and concentrates, and softgel capsules. It offers its products under the Tweed, Quatreau, Deep Space, Spectrum Therapeutics, First & Free, TWD, This Works, BioSteel, DNA Genetics CraftGrow, Tokyo Smoke, DOJA, Van der Pop, and Bean & Bud brands. The company also provides growth capital and a strategic support platform that pursues investment opportunities in the global cannabis sector. Canopy Growth Corporation has a clinical research partnership with NEEKA Health Canada and NHL Alumni Association to examine the efficacy of CBD-based therapies as part of the mitigation of persistent post-concussion symptoms. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Latest CGC
- Director Bayern Joseph sold $2,953 worth of shares (3,197 units at $0.92), decreasing direct ownership by 2% to 145,127 units (SEC Form 4) (withholding tax)
- Director Yanofsky Theresa sold $13,905 worth of shares (15,054 units at $0.92), decreasing direct ownership by 9% to 146,415 units (SEC Form 4) (withholding obligation)
- Director Atkins M Shan sold $2,953 worth of shares (3,197 units at $0.92), decreasing direct ownership by 2% to 146,517 units (SEC Form 4) to cover taxes
- Director Lazzarato David Angelo sold $20,944 worth of shares (22,674 units at $0.92), decreasing direct ownership by 10% to 211,859 units (SEC Form 4) to cover withholding tax
- Director Atkins M Shan was granted 108,324 shares, increasing direct ownership by 262% to 149,714 units (SEC Form 4)
- Director Lazzarato David Angelo was granted 162,485 shares, increasing direct ownership by 226% to 234,533 units (SEC Form 4)
- Director Bayern Joseph was granted 108,324 shares, increasing direct ownership by 271% to 148,324 units (SEC Form 4)
- Director Yanofsky Theresa was granted 108,324 shares, increasing direct ownership by 204% to 161,469 units (SEC Form 4)
- Officer Stewart Thomas Carlton was granted 379,018 shares and sold $9,045 worth of shares (9,285 units at $0.97), increasing direct ownership by 150% to 616,398 units (SEC Form 4) to satisfy withholding tax
- Officer Gedeon Christelle was granted 396,012 shares and sold $57,466 worth of shares (58,994 units at $0.97), increasing direct ownership by 91% to 705,506 units (SEC Form 4) to satisfy withholding tax
Latest NAGE
- Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
- SEC Form 424B5 filed by Niagen Bioscience Inc.
- SEC Form EFFECT filed by Niagen Bioscience Inc.
- Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
- SVP, General Counsel Lopez Carlos Luis was granted 2,314 shares, increasing direct ownership by 103% to 4,565 units (SEC Form 4)
- Chief Financial Officer Pamir Ozan was granted 4,255 shares, increasing direct ownership by 58% to 11,627 units (SEC Form 4)
- Chief Executive Officer Fried Robert N was granted 1,106 shares, increasing direct ownership by 0.10% to 1,060,087 units (SEC Form 4)
- Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
- Niagen Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form S-3 filed by Niagen Bioscience Inc.